DCP as a biomarker for TACE efficacy in hepatocellular carcinoma
Hui Xie1, Youwei Li1, Jie Yang1
1Hepatobiliary Pancreatic Surgery, Deyang People's Hospital, Deyang, Sichuan, China.
Introduction:
Primary hepatocellular carcinoma (PHC) requires advanced diagnostic and therapeutic strategies. While transcatheter arterial chemoembolization (TACE) is a cornerstone treatment, efficacy assessment remains challenging.
Methods:
We retrospectively analyzed 90 PHC patients treated with TACE. Serum DCP levels were measured pre-treatment and at 1, 4, and 8 weeks post-treatment. Treatment response was evaluated using mRECIST criteria.
Results:
Low DCP patients (≤40 mAU/mL) showed significantly higher response rates (53.3%) compared to high DCP (>300 mAU/mL, 30.0%, p<0.05). The hazard ratio for treatment failure was 1.62 (95% CI: 1.09-2.23, p<0.01) per unit increase in log-transformed DCP. Median overall survival was 24.5 months for low DCP versus 12.6 months for high DCP patients (log-rank p<0.001).
Discussion:
DCP serves as a robust biomarker for predicting TACE efficacy, enabling personalized treatment strategies in PHC management.
More Related Videos
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
12:41Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
Published on: December 23, 2022